Clinical Trial

Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 23, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This observational study is a non-interventional, multi-center, prospective observational study aimed at tracking the efficacy and safety of Envlo or Envlomet SR tablets for 24 weeks in patients with type 2 diabetes and hypertension or dyslipidemia who are currently taking or are scheduled to take Envlo or Envlomet SR tablets in an actual clinical setting.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-10-16; most recent amendment 2025-01-21.
Status change: Not Yet Recruiting → Recruiting 2025-01-21
Trial Details
NCT Number NCT06647888
Lead Sponsor Daewoong Pharmaceutical Co. LTD.
Conditions Diabetes Mellitus, Type 2
Enrollment 12,000 participants
Start Date 2024-12-03
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-23